higher risk of relapse, lower quality of life and higher medical costs. The adherence measure, persistency, refers to the duration a patient continues with therapy. This study aims to evaluate the non-pharmacy medical costs associated with the persistency of DMT's in patients with MS. METHODS: A decision-analytic model was designed using persistency rates, health care resource use and costs from the published literature. The model evaluated the medical costs associated with the persistence, switching, and discontinuation rates of patients on interferon β1a IM, interferon β1b SC, and interferon β1a SC over a 2-year time horizon. Using 6-month intervals in the model, patients could switch to a comparator treatment, discontinue treatment, or persist/ remain on their current treatment, and would incur the non-pharmacy medical costs associated with each. For patients who switched treatments, the model assumed an equal probability of switching to the three remaining DMTs. The model also assumed that patients who discontinued therapy would initiate on a different therapy after one month of discontinuing. The overall medical costs related to persisting on treatment, switching treatment or discontinuing treatment were calculated for all treatment arms. RESULTS: Based on the results from the model, an annual per-patient medical cost of $7423 was observed for interferon β1a IM patients, showing a medical cost advantage over patients on interferon β1b SC ($8144; 8.9%), and interferon β1a SC ($7552; 1.7%). CONCLUSIONS: MS is a lifelong disease that requires continuous treatment.
1
Covidien, Zurich, Switzerland; 2 University College London, London, UK; 3 PRMA Consulting, Fleet, UK; 4 Covidien, Fishers, IN, USA OBJECTIVES: Cerebrospinal fl uid (CSF) leak is an unavoidable consequence of cranial surgery with leak rates between 0% to 25% and resulting costs ranging from £9,000 to £36,000. The use of polyethylene glycol (PEG) hydrogel dural sealant as an adjunct to sutured closure has been shown to reduce CSF leak rates as compared with sutures alone in cranial procedures (GR Cosgrove et al, 2007) . Our hypothetical analysis applied the potential cost offsets of using PEG hydrogel sealant as an adjunct to sutured closure in 200 cranial procedures assuming CSF leak rates of 4.5% (9/200) (GR Cosgrove et al, 2007) , compared with 10% (20/200) for fi brin sealant (JA Grotenhuis, 2005) . METHODS: The incremental additional cost for treating CSF leaks using total patient costs for those with CSF leaks (£25,253) compared to those without CSF leaks (£10,497) was estimated at £14,756 in a Dutch study (JA Grotenhuis, 2005) . We applied this CSF leak cost to estimate potential UK hospital cost offsets on 200 hypothetical cranial patients using PEG hydrogel sealant (£300/treatment), compared with fi brin sealant (£133/treatment) on all 200 patients. RESULTS: Use of a PEG hydrogel sealant compared with fi brin sealant could potentially save £137,611 (or £688/patient) for a hospital that performed 200 cranial surgery procedures using a PEG hydrogel sealant compared with using fi brin sealant on all 200 procedures. CONCLUSIONS: This study demonstrates the potential economic advantages of using a PEG hydrogel sealant in cranial procedures. Future clinical direct comparative studies would be benefi cial to confi rm these fi ndings and understand the possible economic advantages for other types of dural surgeries.
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ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY OF 100 PATIENTS
Érsek K 1 , Mikudina B 1 , Arányi Z 2 , Juhos V 3 , Baji P 1 , Péntek M 1 , Brodszky V 1 , Gulácsi L 1 1 Corvinus University of Budapest, Budapest, Hungary; 2 Semmelweis University, Budapest, Hungary; 3 St. István and St. László Hospital, Budapest, Hungary OBJECTIVES: Epilepsy is the second most frequent neurological disease among adults; approximately 50-60 thousand people suffer from epilepsy in Hungary. With our survey we aimed to assess the cost of illness from a societal viewpoint as well as the quality of life associated with epilepsy in Hungary. METHODS: We conducted a cross-sectional questionnaire survey of 100 consecutive patients in 2 epilepsy centres in Hungary in collaboration with epilepsy specialists. The self-developed questionnaire consisted of general and disease-specifi c parts to determine costs associated with epilepsy. Questions related to basic demographic characteristics, disease progression and health and social services used in the past 12 months, disease-associated nonmedical services, as well as the productivity losses of epilepsy. Two generic quality of life questionnaires, EQ-5D and SF-36 were also used. RESULTS: A total number of 100 patients were assessed (60% female). The average age was 36.7 years (SD. 12.5), average disease duration was 15 years (SD. 12). Quality of life calculations resulted in mean of 0.83 (SD. 0.24) in EQ-5D, 74 (SD. 16) in VAS scale and 72.3 (SD. 20.2) in SF-36. Cost-of-illness calculations were carried out and direct (15%) and indirect costs (85%) were determined. The annual total cost of epilepsy per capita was estimated to be a mean of c5179 (SD. c10,822) with the human resource method, while c2,552/capita/year (SD. 8659) by the friction cost method. CONCLUSIONS: Comparing the 100 patients' data with data from previous EQ-5D based population-sample survey shows that quality of life among people with epilepsy was lower than among the average Hungarian population. We found signifi cant correlation (at P < 0.05) among all of the quality of life results and the yearly total costs (calculating both with human capital and friction cost methods).
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LONG-TERM DISABILIY COST IN TUBEROUS SCLEROSIS COMPLEX (TSC) IN BRAZIL
Valentim J Novartis, Sao Paulo, SP, Brazil OBJECTIVES: To estimate long-term disability costs associated with tuberous sclerosis complex, a rare multisystem genetic disease, in Brazil. METHODS: Literature review for TSC long-term disability and economic burden was performed (Pubmed, LILACS, SciELO, CRDs). Cost estimation was limited to epilepsy (most prevalent TSC disorder). Cost of lost productivity in patients since epilepsy onset in childhood and carried in adulthood as well as caregivers' productivity costs were estimated. The Human Capital Method was adopted and potential lost working years estimated till an active age of 65 years. It was assumed a caregiver for all ages. Average income, unemployment rate due to epilepsy, productivity growth and epidemiology data were obtained from the literature and from the Brazilian Institute of Geography and Statistics. Mean annual productivity cost per patient, total productivity cost per patient and the total productivity burden of TSC-related epilepsy were calculated. Costs were estimated in 2008 Reals and discounted at 5%. Univariate sensitivity analysis was conducted for epidemiology data, employment status rate, productivity growth, discount rate and time horizon. RESULTS: Productivity loss was 47, 30 and 65 years for epilepsy onset in childhood and adulthood and caregivers, respectively. The discounted and not discounted mean annual productivity cost per patient were R$1,970 and R$11,323, total productivity cost per patient R$97,882 and R$691,150 and total productivity burden of TSC-related epilepsy in Brazil R$1,568,965,961 and R$11,078,536,271, respectively (1Euro = 3.24Reals). Results were sensitive to all the parameters varied in the sensitivity analysis, especially discount rate. CONCLU-SIONS: TSC-related epilepsy is a chronic disorder associated with loss of productivity with a signifi cant economic burden in Brazil. Although signifi cant, the economic burden related to productivity loss is expected to be even higher since there are still costs deriving from absenteeism of patients and caregivers when employed looking for health services to be included in further analysis.
PND11 NURSE COSTING SURVEY FOR THE MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING DRUGS IN THE UK
Perard R, Parkes L 1 Merck Serono Limited, Feltham, UK OBJECTIVES: To determine the costs and medical resource use for the management of injection-site reactions (ISRs) and fl u-like symptoms (FLS) associated with injectable disease-modifying drugs (DMDs) used to treat patients with relapsing-remitting multiple sclerosis (RRMS) in the UK. METHODS: A survey was carried out amongst NHS nurses to understand the management of adverse events occurring with injectable DMD use. Data were collected via a postal questionnaire. Responses were compiled for the frequency and duration of side-effects, support received and medical consultations required for adverse event management. The unit costs were derived from the Personal Social Services Research Unit, the Offi ce for National Statistics and the British National Formulary. Once all parameters and unit prices were characterised with conservative approaches for missing data (e.g. no GP consultation mandatory before antibiotics prescription), computations were processed to determine means and standard deviations (SDs). RESULTS: In total, 19 NHS nurses managing signifi cant numbers of patients with MS for different primary care trusts participated in the costing survey. On average, the nurses reported that patients experienced 27 ISRs per year of those 33% experienced ISRs only at treatment start while 21% experienced ISRs continuously during the year. Seventy-four percent experienced FLS only at treatment start and 11% continuously. The average cost for the management of ISRs per year was £187 (SD £209) equivalent to an average cost of £7 per event. The average cost for the management of FLS per year was £166 (SD £144) equivalent to an average cost of £6 per event. CONCLUSIONS: This is the fi rst UK study to provide data on the costs associated with management of ISRs and FLS occurring with injectable DMDs. These data, alongside prevalence estimates, enabled us to calculate the costs of managing adverse events associated within DMDs in an economic model.
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EUROPEAN-HUNTINGTON'S DISEASE BURDEN STUDY (EURO-HDB)-PRELIMINARY RESULTS FOR ITALY AND FRANCE
Dorey J 1 , Toumi M 2 , Clay E 1 , Tedroff J 3 , Squitieri F 4 , De Nicola N 4 , Verny C 5 1 Creativ Ceutical, Paris, France; 2 University Claude Bernard Lyon 1, Lyon, France; 3 NEUROSEARCH, Ballerup, Denmark; 4 Neurogenetics and Rare Disease Centre, Pozzilli, Italy; 5 Neurology Unit CHU, Angers, France OBJECTIVES: Huntington's disease (HD) is a rare neurodegenerative disease leading to sustained disability and poor health-related quality of life (HRQOL). As new treatments are in development for HD, data on the burden of disease are required. This study evaluated patient health status, patient and caregiver HRQoL and costs in HD. METHODS: Euro-HDB is a European cross-sectional survey being conducted in eight European countries. Self-reported questionnaires were completed by patients and caregivers. The patient questionnaire includes the Huntington Self-Assessment Instrument, a specifi c tool that assesses clinical characteristics, HRQoL and health care resource utilization. The EQ5D questionnaire and the SF36 Survey are also included. RESULTS: To date, 201 patients have been enrolled in France and 124 in Italy. All levels of disease severity are represented. Average annual costs from societal perspective are c5,325 (±9588), c18,045c (±34487) and c41,716 (±35211) at mild, moderate and severe stages respectively in France; c3,125 (±4319), c8,457 (±18374) and c5,069 (±11747) in Italy. Associated EQ-5D utilities are respectively 0.79 (±0.18), 0.39 (±0.37), −0.11 (±0.3) in France; 0.59 (±0.44), 0.39 (±0.42), 0.25 (±0.44) in Italy. The primary cost driver is productivity loss. In France, hospitalization and nursing home costs are the main components of direct costs. For more severely affected patients, medical resource utilization diminishes while caregiver involvement increases significantly (the shift is greater in Italy than France). Physical, mental and social HRQoL domains are all seriously affected. CONCLUSIONS: Euro-HDB is the fi rst study to comprehensively assess the cost and HRQOL burden of HD. The 1:5 cost ratio (Italy : France) is consistent across most of the cost items, suggesting that differences in health care systems, access to health care and cultural attitudes towards caring for patients at home have a large impact on a country's overall costs. Results suggest that HD has greater impact on HRQOL than Parkinson's disease and Alzheimer's disease. The economic burden of Multiple Sclerosis (MS) on society and the individuals concerned is not known. Documenting such costs is essential for several reasons: costs of illness is a key factor of optimal disease management policies, knowledge of cost is useful for allocating research and development. The aim of our study as the fi rst pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis according to severity of disease. Total, direct and indirect costs were compared in 160 patients divided into three groups categorized by disease severity: stage I Expanded Disability Status Scale (EDSS < 2.5), stage II (EDSS 3-4.5) and stage III (EDSS > 5). The majority of these patients (94%) developed relapsing-remitting MS. a minority of the patients (0.2-4%) developed secondary progressive and primary progressive MS. Cost evaluation was performed from the societal perspective and covered the one-year period. The study was carried out at the Division of Neurology at Ghaem Hospital and MS association in Mashhad in northeast of Iran and was approved by the local ethics committee. The mean total cost/patient for one year was estimated at $27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs increased with MS progression. For indirect cost the main item was productivity loss. The mean extra medicine (treatments for MS symptoms and adverse effects of medications) cost/patient for one year was calculated at $19,036. This study confi rms that MS represents a high economic burden to patients and society, with direct costs greatly exceeding indirect costs. As costs increase with disease progression, treatment efforts should focus on patients in the early stages of MS. Disease support system that monitors a variety of common progressive signs for the MS individuals is a key element of a management program as well.
PND13 A PROSPECTIVE STUDY OF THE FINANCIAL COSTS OF MULTIPLE SCLEROSIS AT DIFFERENT STAGES OF THE ILLNESS IN IRAN
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SOCIO-ECONOMIC ASPECTS OF TESTING FOR NEUTRALIZING ANTIBODIES IN MS PATIENTS ON INTERFERON BETA TREATMENT IN AUSTRIA: A COST OF ILLNESS STUDY
Walter E 1 , Brennig C 1 , Schöllbauer V 1 , Mair W 2 , Deisenhammer F 3 1 Institute for Pharmaeconomic Research, Vienna, Austria; 2 Biogen Idec GmbH, Vienna, Austria; 3 University Hospital Innsbruck, Innsbruck, Austria OBJECTIVES: According to EU-guidelines testing all patients on interferon-beta (IFNb) for presence of neutralizing antibodies (NAB) is recommended irrespective of clinical course and stop IFNb or switch to alternatives in patients who developed persistent NAB; based on the fact that development in persistently NAB-positive patients equals that of placebo-treated patients. Economic impact of NAB-testing in MS-patients has not been explored yet. METHODS: This analysis estimated the economic impact of NAB-testing versus not testing during IFNb treatment in MSpatients (n = 3590) on Austria's health care system. a cost of illness model (decision tree combined with an integrated Markov model, time horizon 5 years), based on the cohort of IFNb-treated patients was performed. Two alternatives were compared: Cost-effectiveness of NAB-testing versus no NAB-testing. The NAB-testing arm allowed switching to alternative therapies whereas no-NAB-testing did not. Direct costs comprised all treatment-costs of symptoms due to MS. Indirect costs were not included. All costs represent data from 2010 (discounted at 5%p.a). Clinical data and resource use were determined by literature/experts. Effi cacy assessment was based on the outcome measure "relapses avoided." RESULTS: Total discounted costs for all Austrian MS-patients on IFNb-therapy (incl. testing) from a health care system's perspective amount to c187,764,180 for 5 years. Total costs for all MS-patients without testing amount to c176,331,610. The difference of costs between tested patients, and therefore switching, and not tested patients values c11,432,570. Considering all IFNb-treated patients and a time horizon of 5 years 1400 relapses can be avoided. Testing for NAB leads to costs per relapse avoided of c24,383p.a. versus c27,569p.a. when no tests are done resulting in a difference of c3,186 per patient in favour of NAB-testing. CONCLUSIONS: General NAB-testing in MS-patients on IFNb-therapy is reasonable and cost-effective. Patients switching to effective and more expensive alternatives do not account for higher health care costs. Furthermore, less relapses increase QoL.
PND15 PATIENT CHARACTERISTICS AND CHARGES ASSOCIATED WITH EMERGENCY DEPARTMENT VISITS AMONG PATIENTS WITH A DIAGNOSIS OF RESTLESS LEGS SYNDROME
Meyers J, Candrilli S RTI Health Solutions, Research Triangle Park, NC, USA OBJECTIVES: Restless legs syndrome (RLS) affects 2 to 15% of the US population. Limited data exist on patient characteristics and charges associated with emergency department (ED) visits among patients with RLS. METHODS: Data from the 2007 Healthcare Cost and Utilization Project's Nationwide Emergency Department Sample were used. Patients were selected for inclusion if they had a diagnosis of RLS (ICD-9-CM code 333.94). Study measures included patient demographics and charges associated with the ED visit. Study measures were reported separately for patients with a primary versus secondary RLS diagnosis. Among patients with a secondary RLS diagnosis, the most common primary diagnoses were reported. RESULTS: A total of 6133 patients with a primary RLS diagnosis and 140,931 patients with a secondary RLS diagnosis were identifi ed. Common primary diagnoses among patients with a secondary RLS diagnosis included respiratory symptoms (7.0%), general symptoms (4.6%), and pneumonia (3.7%). Mean (Std. Err.) age was 54.5 (0.6) years among patients with a primary diagnosis and 64.0 (0.3) years among patients with a secondary diagnosis. In both cohorts, over two-thirds of patients were female, the most common geographic regions were the South and Midwest, and Medicare was the most common primary payer (41.0% of patients with a primary diagnosis and 59.3% of patients with a secondary diagnosis). Over 90% of patients with a primary diagnosis had a routine discharge compared to only 26.6% of patients with a secondary diagnosis, and most patients with a secondary diagnosis were admitted to the facility as an inpatient. Mean (Std. Err.) charges were $816 ($48) for patients with a primary diagnosis and $2,043 ($62) for patients with a secondary diagnosis. CONCLUSIONS: This nationally representative study suggests that patients admitted to the ED with RLS accrue substantial costs during their visit. Further research is needed to more fully assess the total economic burden of the disease.
PND16 MODELING THE CLINICAL AND ECONOMIC IMPLICATIONS OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE IN GERMANY
Guo S 1 , Hernández L 1 , Wasiak R 2 , Gaudig M 3 1 United BioSource Corporation, Lexington, MA, USA; 2 United BioSource Corporation-Europe, London, UK; 3 Janssen-Cilag, Neuss, Germany OBJECTIVES: A reimbursement policy issued by the Federal Joint Committee in Germany to reassess the benefi t of cholinesterase inhibitors every six months in order to receive continued coverage by the Statutory Health Insurance triggered an additional need to periodically assess the cost-benefi t of galantamine in the treatment of mild-to-moderate Alzheimer's disease (AD). An economic model specifi cally designed for the purposes of such an assessment was developed using the most up-to-date IQWiG guidelines for cost-benefi t assessment. METHODS: The model uses a discrete event simulation to predict the course of AD through changes in cognition, behavioral disturbance, and function over time, and compare the costs and benefi ts of galantamine versus no-drug treatment and ginkgo biloba. Clinical data were mainly derived from analyses of pooled data from clinical trials. Epidemiological and cost data were obtained from literature and public data sources. Costs (2009 c) from the perspective of the German Statutory Health Insurance were used. Both costs and benefi ts were discounted at 5%. Sensitivity analyses were performed to assess the robustness of the model outcomes. RESULTS: Over a 10-year period, galantamine on average delays time to severe stage of the disease by 3.57 and 3.36 months, compared to no-drug treatment and ginkgo biloba, respectively. Galantamine also reduces time spent institutionalized by 2.34 and 2.21 months, compared to no-drug treatment and ginkgo biloba, respectively. The use of galantamine is projected to yield net savings of c3,978 and c3,972 per patient compared to respective treatments. CONCLUSIONS: Our analyses suggest that compared to no-drug treatment and ginkgo biloba, treatment with galantamine not only improves clinical benefi ts, but also achieves savings in health care costs associated with care for patients with mild-to-moderate AD in Germany.
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MEMANTINE DELAYS THE ADMISSION OF ALZHEIMER'S DISEASE PATIENTS TO NURSING HOME: COST-EFFECTIVENESS ANALYSIS IN FRANCE
Touchon J 1 , Lachaine J 2 , Beauchemin C 2 , Crochard A 3 , Rive B 3 , Bineau S 3 1 Gui de Chauliac Hospital, Montpellier, France; 2 University of Montreal, Montreal, QC, Canada; 3 Lundbeck SAS, Issy-Les-Moulineaux, France OBJECTIVES: To evaluate in the French setting the cost-effectiveness of memantine as adjunct therapy to Cholinesterase inhibitors (ChEI) compared to ChEI monotherapy in Alzheimer's disease (AD) patients. METHODS: A cost-effectiveness analysis employed a 3-state Markov model ("non-institutionalized," "institutionalized" and "dead") and compared the treatment alternatives in terms of time to nursing home admission, Quality Adjusted Life-years (QALYs), and costs over a 7-year time horizon. Annual transition probabilities between states were derived from two observational cohort studies: Lopez et al 2009 (US) for institutionalization probabilities and Helmer et al 2001 (FR) for death probabilities. Costs were valued from health care system and societal perspectives, and included cost of AD medications (French National
